Manish Thakur, MD
Medical Oncology · Grand Rapids, MINPI 1093022386
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,775 of the $17,424 with a category attached, or 90.5%. 24 manufacturers reported payments, led by Daiichi Sankyo Inc. at 45.3% of the total. 2025 is the largest year on record at $9,782, more than ten times the $204 reported in 2019.
Across 45 payments — averaging $387.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$8K
- Johnson & Johnson$3K
- Regeneron$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Pfizer$2K
- Galvanize Therapeutics, Inc$315
- plus $567 from 18 others
Across 4 payments — averaging $10,998 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$24K
- Genentech, Inc.$20K
What the payments were for
- Consulting fees$15,77591%
- Travel & lodging$4072%
- Food & beverage$1,0056%
- Education$2371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 5 | $7,894 |
| Johnson & Johnson | 8 | $2,834 |
| Regeneron | 2 | $2,113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,040 |
| Pfizer | 3 | $1,662 |
| Galvanize Therapeutics, Inc | 1 | $315 |
| Seagen Inc. | 1 | $100 |
| AstraZeneca | 3 | $70 |
| Array Biopharma Inc | 2 | $43 |
| Puma Biotechnology, Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Eisai Inc. | 2 | $30 |
| AbbVie | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $25 |
| Sanofi | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| Merck | 1 | $18 |
| GSK | 1 | $18 |
| Bristol Myers Squibb | 1 | $16 |
| Lilly USA, LLC | 1 | $12 |
| EMD Serono, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,424 in reported general payments places this provider in the 75th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 41 | $903,969 |
| XtandiEnzalutamide | 13 | $174,475 |
| BosulifBosutinib | 14 | $142,439 |
| EliquisApixaban | 27 | $19,625 |
| Anastrozole | 99 | $4,356 |
| Exemestane | 18 | $3,448 |
| Dexamethasone | 131 | $1,373 |
| Prochlorperazine Maleate | 117 | $1,340 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,107 |
| Tamoxifen Citrate | 38 | $1,104 |
| Fentanyl | 11 | $946 |
| Ondansetron OdtOndansetron | 105 | $887 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 65 | $618 |
| Letrozole | 28 | $574 |
| Mirtazapine | 23 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $70 | $903,96941 claims |
| PfizerBosulif, Eliquis | $1,662 | $162,06441 claims |
| Lilly USA, LLCOlanzapine | $12 | $33175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Grand Rapids
- Sami BrakeGrand Rapids$251K
- Anas AljanadiGrand Rapids$62K
- Zeyad SakoGrand Rapids$10K
- Harry ErbaAnn Arbor$1.1M
- Philip PhilipDetroit$494K
- Shirish GadgeelDetroit$413K
- Patricia Lo RussoDetroit$322K
- Ammar SukariDetroit$273K
- Frank WeinbergAnn Arbor$195K
- Wajahat KhanGrosse Pointe Woods$190K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.